Sanofi Viscosupplement Growth in Emerging Markets Offsets U.S. Losses

Sanofi reported 3Q19 Synvisc revenue of €73 million (USD $82 million), +1.4% vs. 3Q18.

Sanofi’s U.S. viscosupplement sales rebounded somewhat after 2Q19, in which they were down double-digits year over year
Continued strength in emerging markets offset U.S. losses, bringing positive growth for Synvisc for the first time in 2019

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us